.
MergerLinks Header Logo

Announced

Completed

Cerus-backed Opocrin completed the acquisition of Laboratori Derivati Organici.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

organotherapeutic products

Completed

Majority

Single Bidder

Pharmaceuticals

Friendly

Acquisition

Italy

Synopsis

Edit

Boutique office management firm Cerus Advisors-backed Opocrin, a global manufacturer of active pharmaceutical ingredients, completed the acquisition of Laboratori Derivati Organici, a pharmaceutical company. Financial terms were not disclosed. "Cerus Advisors has dedicated significant time and resources to the development of LDO over the last 9 years and this transaction represents the culmination of these efforts. We are also pleased with the creation of a group that has significant potential for continued value creation for its shareholders," Marios Fotiadis, Cerus Chairman, Manager Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US